The Brockman Foundation has provided funding for the first clinical trial of chemoembolization, which involves injecting chemotherapy directly into the artery suppling lung metastases, in the United States.
The research is being led by Dr. F. Edward Boas, an interventional radiologist at Memorial Sloan Kettering Cancer Center, who specializes in performing minimally invasive cancer therapies: embolization, chemoembolization, radioembolization, and ablation.
Patients with multiple lung metastases are typically treated using chemotherapy. If the metastases do not respond to chemotherapy then the patient has limited treatment options. Delivering chemotherapy directly into the metastases can improve the response rate, while reducing systemic side effects. This has been tried in Europe and Asia, with promising initial results.
Using lessons learned from prior studies, Dr. Boas and his team have designed the first clinical trial of lung chemoembolization in the US. Lung chemoembolization could enable treatment of large and multifocal lung metastases (including hilar lymph nodes) in patients with no other treatment options.
Dr. Boas received his undergraduate degree in biochemistry at Harvard University, and was awarded his M.D., and Ph.D. Degrees at Stanford University School of Medicine. He completed his residency in Radiology at Stanford and took a Fellowship in Interventional Radiology at the University of Pennsylvania School of Medicine. His laboratory develops new devices, drugs, and procedures for treating liver, pancreatic, and lung cancer.
- Overview: Multiple lung metastases